Neurotrope Initiates Phase 2a Study of Bryostatin for the Treatment of Alzheimer's Disease - Doses First PatientsJuly 29, 2014 9:13 am | News | Comments
Neurotrope announced today that it has initiated a Phase 2a clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease (AD). Bryostatin is a potent modulator of the enzyme protein kinase C epsilon (PKCe).
Two American aid workers have tested positive for the Ebola virus while working to combat an...
When it comes to preventing the spread of germs, maybe the president is on to something with his...
Prosecutors in Northern California said Thursday that they have obtained an arrest warrant for a...
New research casts doubt on the most common treatment for lower back pain. Also, checking your pulse frequently after a stroke may be the best way to prevent another stroke.
Humans are a strange lot. We are more than willing to believe just about any product claim in the hopes that an easy solution to our problem can be found inside a pill, tablet or liquid.
A new study is raising questions about a common hysterectomy procedure, power morcellation, that may spread cancer that has not yet been detected.
Experimentation with human growth hormones by America's teens more than doubled in the past year, as more young people looked to drugs to boost their athletic performance and improve their looks, according to a new, large-scale national survey.
Health officials on Monday advised patients of a West Virginia pain management clinic to be tested for blood-borne infectious diseases after an investigation found that needles had been reused.
Scientists have linked more than 100 spots in our DNA to the risk of developing schizophrenia, casting light on the mystery of what makes the disease tick. Such work could eventually point to new treatments, although they are many years away. Already, the new results provide the first hard genetic evidence to bolster a theory connecting the immune system to the disease.
A case challenging Arizona's refusal to reveal detailed information about the lethal drugs it plans to use to put an inmate to death is now headed to the U.S. Supreme Court. The dispute centers on whether a man convicted of killing his estranged girlfriend and her father has a constitutional right to know more about his execution than Arizona officials have been willing to disclose.
Johns Hopkins Hospital has agreed to a $190 million settlement with more than 8,000 patients of a gynecologist who secretly photographed and videotaped women's bodies in the examining room with a pen-like camera he wore around his neck.
Researchers have been working on an AIDS vaccine since the 1980s. So what's taking so long?
Health alert issued for the viral disease that originated in the Caribbean.
An international AIDS conference opened in Australia on Sunday with a tribute to several delegates who were killed en route to the gathering when their plane was shot down over Ukraine.
A Rhode Island firefighter who got an infection after being pricked by a thorn has lost his hand to flesh-eating bacteria.
Results From Phase 3 VIVID-DME Trial of EYLEA Injection for the Treatment of Diabetic Macular Edema Show Sustained ImprovementJuly 18, 2014 9:31 am | News | Comments
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that in the Phase 3 VIVID-DME trial of EYLEA (aflibercept) Injection for the treatment of diabetic macular edema showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
AstraZeneca today revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK. The plans for the new facility, which will be located on the Cambridge Biomedical Campus (CBC), include designs for the Global Centre, an R&D Enabling Building and an Energy Centre.
Scientists at the Salk Institute have identified a gene responsible for stopping the movement of cancer from the lungs to other parts of the body, indicating a new way to fight one of the world's deadliest cancers.
The road to finding a cure for HIV-1 is not without obstacles. However, thanks to cutting-edge research performed at the George Washington University (GW), Oregon Health & Science University, the University of Rochester, and UC San Francisco, the scientific community is one step closer to finding a viable immunotherapy option for HIV-1, using an immune attack against a fossil virus buried in the genome.
The Mayo Clinic is testing the safety and effectiveness of taking stem cells from a patient's own fat and injecting them into their spinal fluid to slow the progression of ALS.
No batteries required: Scientists are creating a biological pacemaker by injecting a gene into the hearts of sick pigs that changed ordinary cardiac cells into a special kind that induces a steady heartbeat.
New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use.
The rate of Alzheimer's disease and other dementias is falling in the United States and some other rich countries — good news about an epidemic that is still growing simply because more people are living to an old age, new studies show.
The number of people living with HIV worldwide has remained virtually unchanged in the past two years and AIDS-related deaths are at their lowest since peaking almost a decade ago, according to a report from the United Nations AIDS agency released Wednesday.
A nine year old Kansas girl is the latest victim of a rare brain infection that lives in warm, standing water.
While the global epidemic of Alzheimer's disease continues to grow, new data on lower incidence in the "youngest old" from developed countries in Europe and the United States suggest the possibility of reducing risk and/or preventing the disease, according to the results of several research studies announced at the Alzheimer's Association International Conference.
In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer’s disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil.
- Page 1